AI Insight
This commentary discusses endothelin receptor A (ETA) antagonists as a potential treatment for IgA nephropathy, a kidney disease. In IgA nephropathy, endothelin-1 is overexpressed in the kidneys and contributes to kidney damage through multiple mechanisms including vasoconstriction, cell proliferation, inflammation, and fibrosis. The biological rationale for targeting this pathway has generated interest in using ETA antagonists for treating this condition and other chronic kidney diseases.
Why it matters
If effective, endothelin receptor antagonists could provide a new treatment option for IgA nephropathy, which currently has limited therapeutic options and can progress to kidney failure. The mechanistic understanding of how endothelin-1 drives kidney damage offers a scientifically grounded basis for developing targeted therapies.
Endothelin biology remains an attractive therapeutic target in IgA nephropathy where intrarenal endothelin-1 expression is upregulated and implicated in nephron loss through vasoconstriction, mesangial cell proliferation, inflammation, apoptosis and fibrosis.1 This mechanistic rationale has driven renewed interest in endothelin receptor A (ETA) antagonists (ERAs) across chronic kidney disease, including IgA nephropathy.2
Source: [Comment] Endothelin antagonism in IgA nephropathy: promise ahead of proof?